Pittock, Sean J. http://orcid.org/0000-0002-6140-5584
Zekeridou, Anastasia
Weinshenker, Brian G. http://orcid.org/0000-0001-5806-6203
Article History
Accepted: 22 September 2021
First Online: 28 October 2021
Competing interests
: S.P. reports grants, personal fees and non-financial support from Alexion Pharmaceuticals; grants, personal fees, non-financial support and other support from MedImmune/VielaBio; and personal fees for consulting from Genentech/Roche. He is a named inventor on patent 8,889,102 (Application US12/678,350, Neuromyelitis optica autoantibodies as a marker for neoplasia) and a named inventor and assignee on patent 9,891,219B2 (Application US12/573,942, Methods for treating neuromyelitis optica [NMO] by administration of eculizumab to an individual who is aquaporin 4 (AQP4)-IgG autoantibody positive). B.G.W. receives royalties from Hospices Civil de Lyon, MVZ Labour PD Dr. Volkmann und Kollegen GbR, Oxford University, and RSR for a patent of NMO-IgG as a diagnostic test for neuromyelitis optica spectrum disorders. He has served on adjudication committees for clinical trials in neuromyelitis optica spectrum disorders conducted by Alexion and MedImmune/VielaBio, and has consulted for Chugai/Roche/Genentech and Mitsubishi–Tanabe regarding clinical trial design for neuromyelitis optica spectrum disorders. He has also received honoraria for speaking at internal meetings of Genentech and Novartis and at external meetings for Roche. A.Z. declares no competing interests.